Do we have enough evidence for recommending therapeutic apheresis for natalizumab ‐related progressive multifocal leukoencephalopathy patients? Comment on “Guidelines on the use of therapeutic apheresis in clinical practice‐evidence‐based approach from the Writing Committee of the American Society for apheresis: The seventh special issue.”